Boehringer chief says China’s drug research rise should spur rivals

By
Stonehaven Analytics
/
Oct 31, 2026

Boehringer Ingelheim chief executive Shashank Deshpande says Europe and the US have “no monopoly on innovation” and argues that China’s fast-growing drug research should push Western drugmakers to compete harder. The family-owned group is also betting on AI, partnering with Microsoft to explore digital patient twins that could make clinical trials faster and more efficient.

Boehringer Ingelheim chief executive Shashank Deshpande says China’s rapid rise in drug development should spur competition rather than alarm among European and US pharmaceutical companies.
“Competition is good for business. Europe and America have no monopoly on innovation,” Deshpande said in an interview on the sidelines of the Asia-Pacific Conference of German Business in Seoul, adding that good science is increasingly coming from China.

His comments come as Chinese biotechs gain ground in early-stage drug discovery and become a growing source of licensed assets for Western drugmakers. For Boehringer, the family-owned German group that is also one of the world’s largest animal health companies, the message is that access to science wherever it emerges matters more than defending regional advantage.

Deshpande also highlighted artificial intelligence as a force that could fundamentally change pharmaceutical research. Boehringer recently announced a strategic collaboration with Microsoft to explore AI-powered digital patient twins: computer models of individual patients that use clinical and other data to predict how a disease may progress under different scenarios. The collaboration was announced on 22 October during Microsoft’s Frontier Tour in Cologne.

The partnership will examine disease-progression modelling, predictive outcome modelling, patient stratification and advanced trial simulation. One aim is to create synthetic or hybrid control arms, potentially reducing the number of patients who need to receive placebo in conventional trials. Boehringer says it is not trying to replace entire trials.

Success could shorten development timelines and cut costs, strengthening Boehringer’s ability to compete as research capabilities spread across Asia.

"This news service is powered by an AI tool that curates and enhances the content related to animal health. The articles provided are for informational purposes only and should not be considered professional or veterinary advice. The content presented does not reflect the views or opinions of Stonehaven Analytics."

Scroll to Top